Cambridge Cognition Holdings PLC Alzheimer's drug potential for Cambridge Cognition
October 25 2019 - 1:00AM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
25 October 2019
Cambridge Cognition Holdings Plc
("Cambridge Cognition" or the "Company")
Renewed promise for early Alzheimer's drug signals potential for
Cambridge Cognition's assessment solution
Following a consultation with the U.S. Food and Drug
Administration ("FDA"), Biogen (Nasdaq : BIIB) and Eisai, Co., Ltd
(Tokyo, Japan) have announced plans to pursue regulatory approval
for aducanumab, which would be the first therapy to tackle clinical
decline in early Alzheimer's disease. If successful, this presents
an opportunity for Cambridge Cognition whose CANTAB(TM) assessments
are specifically sensitive to the early cognitive decline during
Alzheimer's disease.
Despite initial concerns about the efficacy of aducanumab, new
analysis of an expanded dataset has revealed positive results at
higher doses of the drug and Biogen have indicated that they will
file for approval in the U.S. early next year. If approved, this
will be the first drug to slow the progression of Alzheimer's
disease; a major therapeutic breakthrough, as there have been no
new treatments approved since 2003.
This promising step forward for Alzheimer's disease raises the
urgent challenge of finding and assessing patients who are most
likely to benefit from such drugs. Cambridge Cognition's CANTAB
Mobile(TM) can support clinicians in making this decision.
CANTAB Mobile(TM) delivers an automated memory assessment and
depression scale to distinguish older patients who have concerns
about their memory from those at increased risk of dementia.
Available in over 20 languages, this CE-marked, FDA-cleared and
TGA-approved medical device is poised to help clinicians all over
the world identify patients who are most likely to benefit from
disease-modifying treatments.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"We were delighted to hear the news of Biogen's re-invigorated
Alzheimer's programme, as it holds promise for the millions of
people worldwide who are affected by the disease. We are therefore
preparing for the approval of disease modifying treatments so that
patients and families can benefit from new therapies as soon as
possible. CANTAB Mobile(TM) is a medical device that can help
clinicians in identifying the right patients for these potential
new treatments."
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Nick Walters, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Manasa Patil (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company
developing digital health products to better understand, detect and
treat conditions affecting brain health. The company's software
products assess cognitive health in patients worldwide to improve
clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare
industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAXELAEENFFF
(END) Dow Jones Newswires
October 25, 2019 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024